title: Hypoxic conditioned culture medium from fibroblasts grown under embryonic-like conditions supports healing following post-laser resurfacing.
abstract: OBJECTIVE
  Treatment of facial skin perturbed by laser resurfacing with a novel, topical hypoxic conditioned culture medium (HCCM) product results in apparent, accelerated wound recovery time. The HCCM product is conditioned by neonatal fibroblasts under hypoxic conditions and used as the active ingredient in a formulated topical lotion. The HCCM contains significant quantities of growth factors such as vascular endothelial growth factor, keratinocyte growth factor, and interleukin-8. As these molecules are known to play an important role in normal wound healing in vivo, we conducted a pilot clinical evaluation "Proof of Concept" in which individuals, after receiving laser resurfacing, were instructed to use either active or placebo lotion on their abraded skin.
  
  
  METHODS
  The end points used were clinical assessment of the time to complete healing, clinical and bioinstrumental mexameter measurements of erythema, and the number of days of rescue petrolatum use by patients, post-laser.
  
  
  RESULTS
  Day 7, post-laser treatment, resulted in a greater improvement in erythema, and re-epithelization of the peri-oral and peri-ocular regions in subjects using the active lotion vs. placebo control as determined by blinded, clinical evaluation of gross photographs and bioinstrumental mexameter measurements. A statistically significant reduction in rescue petrolatum use in active lotion-treated subjects was reported. Finally, no attendant cutaneous safety concerns (e.g., irritant/allergic dermatitis) were reported with either active or placebo lotion.
  
  
  CONCLUSIONS
  This HCCM product may have broad applications within the field of skin wound repair.
authors.affiliation: Histogen, Inc., La Jolla, California, USA. rkellar@histogeninc.com
authors.forename: Robert S
authors.initials: RS
authors.lastname: Kellar
authors.forename: Mark
authors.initials: M
authors.lastname: Hubka
authors.forename: Lawrence A
authors.initials: LA
authors.lastname: Rheins
authors.forename: Garth
authors.initials: G
authors.lastname: Fisher
authors.forename: Gail K
authors.initials: GK
authors.lastname: Naughton
mesh_terms: D019149:Bioreactors; D015687:Cell Hypoxia / Q000502:physiology*; D064987:Cell- and Tissue-Based Therapy / Q000379:methods; D003470:Culture Media; D017077:Culture Media, Conditioned / Q000494:pharmacology; D051523:Fibroblast Growth Factor 7 / Q000032:analysis / Q000627:therapeutic use; D005347:Fibroblasts / Q000166:cytology* / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D016209:Interleukin-8 / Q000032:analysis / Q000627:therapeutic use; D053685:Laser Therapy / Q000009:adverse effects; D012038:Regeneration / Q000187:drug effects; D012449:Safety; D042461:Vascular Endothelial Growth Factor A / Q000032:analysis / Q000627:therapeutic use; D014945:Wound Healing
chemical_list: D003470:Culture Media; D017077:Culture Media, Conditioned; D016209:Interleukin-8; D042461:Vascular Endothelial Growth Factor A; D051523:Fibroblast Growth Factor 7